Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15774886 | 1.00 | MALT1 (0.36) | MALT1EPHA2ERBB2EPHB4PIK3CD | |
| SCHEMBL15774924 | 1.00 | MALT1 (0.36) | MALT1EPHA2ERBB2EPHB4PIK3CD | |
| SCHEMBL15774925 | 1.00 | MALT1 (0.36) | MALT1EPHA2ERBB2EPHB4PIK3CD | |
| SCHEMBL15775169 | 1.00 | MALT1 (0.36) | MALT1EPHA2ERBB2EPHB4PIK3CD | |
| SCHEMBL18909927 | 0.91 | EPHA2 (0.32) | MALT1EPHA2ERBB2EPHB4PIK3CD | |
| SCHEMBL15656279 | 0.85 | EPHA2 (0.39) | MALT1EPHA2ERBB2EPHB4PIK3CD | |
| SCHEMBL14242319 | 0.85 | EPHA2 (0.39) | MALT1EPHA2ERBB2EPHB4PIK3CD | |
| SCHEMBL19495403 | 0.85 | EPHA2 (0.39) | MALT1EPHA2ERBB2EPHB4PIK3CD | |
| SCHEMBL15656277 | 0.85 | EPHA2 (0.39) | MALT1EPHA2ERBB2EPHB4PIK3CD | |
| SCHEMBL12527146 | 0.82 | EPHA2 (0.47) | MALT1EPHA2ERBB2EPHB4PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| EP-2928888-A1 | SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS | Hutchison Medipharma Limited (CN) | 2015-10-14 | — | — | EP | disclosed |
| WO-2014086316-A1 | SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | SYK, BTK, LYN | MALT1 123/4885EPHA2 776/4885ERBB2 50/4885 |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | SYK, BTK, LYN | MALT1 123/4885EPHA2 776/4885ERBB2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.